BOSTON, Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025.
The call can be accessed via teleconference at: Q3 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/63jte4ra
A replay of the conference call and webcast will be available for one year beginning on February 6, 2025 at 11:00 am ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | ||
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations | |
(781) 356-9763 | (203) 733-4987 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
Media Contact: | ||
Josh Gitelson, Sr. Director-Global Communications | ||
(781) 356-9776 | ||
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$51.35 |
| Daily Change: | 0.01 0.02 |
| Daily Volume: | 403,548 |
| Market Cap: | US$2.470B |
August 07, 2025 May 08, 2025 February 24, 2025 February 06, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
